<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01578070</url>
  </required_header>
  <id_info>
    <org_study_id>VSG-2011-101</org_study_id>
    <nct_id>NCT01578070</nct_id>
  </id_info>
  <brief_title>Single-center Study Evaluating the Safety and Efficacy of Viscogel® as Adjuvant in Act-HIB® Vaccine</brief_title>
  <acronym>VSG-2011-101</acronym>
  <official_title>A Single-centre Study Evaluating the Safety of ViscoGel® and Its Safety and Efficacy as an Adjuvant in Act-HIB® Vaccine Administered by Intramuscular Injection to Healthy Volunteers in a Single-blind Randomised, Parallel-group Design</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Viscogel AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pharma Consulting Group AB</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Viscogel AB</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to show that ViscoGel® is safe when administrated alone and as&#xD;
      an adjuvant together with Act-HIB® vaccine in healthy volunteers and to evaluate the&#xD;
      quantitative and qualitative effect on the immune response.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and type of adverse events, severe adverse events and SUSAR</measure>
    <time_frame>Up to 28 days post injection</time_frame>
    <description>Phase A: 3 consecutive groups each of 10 subjects. Planned dose of ViscoGel® (provided that the data safety monitoring board deemed the previous dose level to be safe): 25mg, 50mg and 75mg.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in HIB antibody serum titer</measure>
    <time_frame>28 days post vaccination</time_frame>
    <description>Phase B: The ViscoGel® dose administrated will be chosen after evaluation of safety and tolerance in Phase A. 2 subjects from group 1 and 2 subjects from group 3 will initially receive ViscoGel® dose (from phase A) with Act-HIB non-randomized. The remaining subjects will be randomized to 5 different treatment arms. Group 1; ViscoGel® with 0.2µg Act-HIB, Group 2; 0.2µg Act-HIB, Group 3; ViscoGel® with 2µg Act-HIB, Group 4; 2µg Act-HIB and Group 5 10µg Act-HIB is given. Blood samples are obtained at baseline and post-injection for assessment of HIB antibody serum titer.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">130</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>ViscoGel® and 0.2μg Act-HIB®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>0.2μg Act-HIB®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ViscoGel® and 2μg Act-HIB®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2μg Act-HIB®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>10μg Act-HIB®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>0.2μg Act-HIB®</intervention_name>
    <description>0.2μg Act-HIB® vaccine, IM (intramuscular) on day 0 of phase B.</description>
    <arm_group_label>0.2μg Act-HIB®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ViscoGel® and 0.2μg Act-HIB®</intervention_name>
    <description>Pre-selected dose of ViscoGel® (from phase A) and Act-HIB® vaccine, IM (intramuscular) on day 0 of phase B.</description>
    <arm_group_label>ViscoGel® and 0.2μg Act-HIB®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ViscoGel® and 2μg Act-HIB®</intervention_name>
    <description>Pre-selected dose of ViscoGel® (from phase A) and 2μg Act-HIB® vaccine, IM (intramuscular) on day 0 of phase B.</description>
    <arm_group_label>ViscoGel® and 2μg Act-HIB®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>2μg Act-HIB®</intervention_name>
    <description>2μg Act-HIB® vaccine, IM (intramuscular) on day 0 of phase B.</description>
    <arm_group_label>2μg Act-HIB®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>10μg Act-HIB®</intervention_name>
    <description>Clinical standard dose of 10μg Act-HIB® vaccine, IM (intramuscular) on day 0 of phase B.</description>
    <arm_group_label>10μg Act-HIB®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects who have signed a written informed consent consistent with ICH GCP guidelines&#xD;
             and local legislations prior to participation in the trial.&#xD;
&#xD;
          -  Subjects who are healthy and with no relevant medical history as determined by the&#xD;
             investigator.&#xD;
&#xD;
          -  Subject that has not previously been known to be infected with or vaccinated against&#xD;
             HIB, or exposed to patients diseased with HIB within a 4 months period prior to&#xD;
             screening.&#xD;
&#xD;
          -  Male and non-lactating female subjects 22-50 years of age.&#xD;
&#xD;
          -  Two negative pregnancy tests if female (at screening and day 0)&#xD;
&#xD;
          -  Contraceptive use if female i.e. using a highly effective contraceptive method&#xD;
             (implants, injectables, combined oral contraceptives, intra-uterine devices [including&#xD;
             hormonal intra-uterine devices], sexual abstinence or vasectomised partner) for at&#xD;
             least one month before dosing and willing to use it for at least one month after&#xD;
             dosing.&#xD;
&#xD;
          -  Able to read and write Swedish.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known allergy to any component in Act-HIB, or who have had a serious reaction after&#xD;
             previous administration of a vaccine.&#xD;
&#xD;
          -  Fever or acute disease including fever.&#xD;
&#xD;
          -  Receipt of immunoglobulins or blood products within three months prior to screening.&#xD;
&#xD;
          -  Donation of blood or suffered of blood loss of 450 ml within 3 months (4 months if&#xD;
             female) prior to screening.&#xD;
&#xD;
          -  Donation of plasma within 14 days prior to screening.&#xD;
&#xD;
          -  Participation in other clinical study within 3 months prior to screening or previously&#xD;
             dosed in this study.&#xD;
&#xD;
          -  Known or suspected immunodeficiency.&#xD;
&#xD;
          -  Vaccination received within a 2 months period prior to screening.&#xD;
&#xD;
          -  Any condition where regular use of inhaled, topical or oral corticosteroid is used.&#xD;
&#xD;
          -  Any condition where use of immunosuppressant is needed, e.g rheumatoid arthitis,&#xD;
             cancer, transplantation, or treatment with immunomodulators, e.g. anti-TNF alpha,&#xD;
             methotrexte, thioguanine, cyclophosphamide, cyclosporine, tacrolimus.&#xD;
&#xD;
          -  Smoker or user of other nicotine products at the discretion of the investigator.&#xD;
&#xD;
          -  Drug or alcohol abuse or history of drug or alcohol abuse in the past 5 years prior to&#xD;
             screening.&#xD;
&#xD;
          -  Any medical condition or other circumstances that in the opinion of the investigator&#xD;
             might interfere with the study.&#xD;
&#xD;
          -  Abnormal clinically significant laboratory values, ECG findings, vital signs or&#xD;
             physical examination findings as judged by the investigator.&#xD;
&#xD;
          -  Inability to adhere to the protocol including plans to move from the area.&#xD;
&#xD;
          -  Use of any prohibited medication (including dietary supplements and herbal medication)&#xD;
             within 2 weeks or 7 half-lives (whichever is longer) of day 0.&#xD;
&#xD;
          -  Any positive result at screening for serum hepatitis B surface antigen (HBsAG),&#xD;
             hepatitis C antibody (anti-HCV) or human immunodeficiency virus (HIV) I and II.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nabil Al-Tawil, MD/PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>KTA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Karolinska Trial Alliance</name>
      <address>
        <city>Stockholm</city>
        <zip>SE-141 86</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <study_first_submitted>April 11, 2012</study_first_submitted>
  <study_first_submitted_qc>April 12, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 16, 2012</study_first_posted>
  <last_update_submitted>August 29, 2013</last_update_submitted>
  <last_update_submitted_qc>August 29, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 30, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Other and Unspecified Vaccines and Biological Substances Causing Adverse Effects in Therapeutic Use</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Salicylic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

